382 related articles for article (PubMed ID: 29968311)
21. Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study.
Loft ND; Egeberg A; Rasmussen MK; Bryld LE; Gniadecki R; Dam TN; Iversen L; Skov L
Acta Derm Venereol; 2019 Dec; 99(13):1224-1230. PubMed ID: 31580465
[TBL] [Abstract][Full Text] [Related]
22. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients.
Norlin JM; Steen Carlsson K; Persson U; Schmitt-Egenolf M
Br J Dermatol; 2012 Apr; 166(4):797-802. PubMed ID: 22182212
[TBL] [Abstract][Full Text] [Related]
23. Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres.
Balogh O; Brodszky V; Gulácsi L; Herédi E; Herszényi K; Jókai H; Kárpáti S; Baji P; Remenyik É; Szegedi A; Holló P
Eur J Health Econ; 2014 May; 15 Suppl 1():S101-9. PubMed ID: 24832841
[TBL] [Abstract][Full Text] [Related]
24. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
Shikiar R; Willian MK; Okun MM; Thompson CS; Revicki DA
Health Qual Life Outcomes; 2006 Sep; 4():71. PubMed ID: 17005043
[TBL] [Abstract][Full Text] [Related]
25. Psychometric properties of the Chinese version of Dermatology Life Quality Index (DLQI) in 851 Chinese patients with psoriasis.
He Z; Lu C; Basra MK; Ou A; Yan Y; Li L
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):109-15. PubMed ID: 22145712
[TBL] [Abstract][Full Text] [Related]
26. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).
Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):452-6. PubMed ID: 24911993
[TBL] [Abstract][Full Text] [Related]
27. Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.
Norlin JM; Calara PS; Persson U; Schmitt-Egenolf M
J Dermatolog Treat; 2017 Sep; 28(6):500-504. PubMed ID: 28132580
[TBL] [Abstract][Full Text] [Related]
28. Moderate Psoriasis: A Proposed Definition.
Llamas-Velasco M; de la Cueva P; Notario J; Martínez-Pilar L; Martorell A; Moreno-Ramírez D
Actas Dermosifiliogr; 2017 Dec; 108(10):911-917. PubMed ID: 28823420
[TBL] [Abstract][Full Text] [Related]
29. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
[TBL] [Abstract][Full Text] [Related]
30. Frequency and influence of "not relevant" responses on the Dermatology Life Quality Index among adults with atopic dermatitis.
Barbieri JS; Chiesa Fuxench ZC; Shin DB; Takeshita J
Qual Life Res; 2021 Jun; 30(6):1705-1713. PubMed ID: 33538979
[TBL] [Abstract][Full Text] [Related]
31. Impact of psoriasis on quality of life in Iran.
Aghaei S; Moradi A; Ardekani GS
Indian J Dermatol Venereol Leprol; 2009; 75(2):220. PubMed ID: 19293529
[TBL] [Abstract][Full Text] [Related]
32. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
Viswanathan HN; Mutebi A; Milmont CE; Gordon K; Wilson H; Zhang H; Klekotka PA; Revicki DA; Augustin M; Kricorian G; Nirula A; Strober B
Value Health; 2017 Sep; 20(8):1174-1179. PubMed ID: 28964451
[TBL] [Abstract][Full Text] [Related]
33. The relationship between quality of life and the severity of psoriasis in Turkey.
Çakmur H; Derviş E
Eur J Dermatol; 2015 Apr; 25(2):169-76. PubMed ID: 25655046
[TBL] [Abstract][Full Text] [Related]
34. Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population.
Norris D; Photiou L; Tacey M; Dolianitis C; Varigos G; Foley P; Baker C
J Dermatolog Treat; 2017 Dec; 28(8):731-736. PubMed ID: 28489479
[TBL] [Abstract][Full Text] [Related]
35. Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey.
Moradi M; Rencz F; Brodszky V; Moradi A; Balogh O; Gulácsi L
Arch Iran Med; 2015 Mar; 18(3):153-9. PubMed ID: 25773688
[TBL] [Abstract][Full Text] [Related]
36. Measuring quality of life in patients with psoriasis using the Arabic version for Morocco of the Dermatology Life Quality Index.
Khoudri I; Lamchahab FZ; Ismaili N; Senouci K; Hassam B; Abouqal R
Int J Dermatol; 2013 Jul; 52(7):795-802. PubMed ID: 23488573
[TBL] [Abstract][Full Text] [Related]
37. PSOdisk is a reliable, intuitive instrument for the evaluation of psychological distress, which strongly correlates with DLQI: a preliminary study.
Cozzani E; Linder D; Burlando M; Gallo F; Sampogna F; Bruzzone M; Tacchino C; Drago F; Parodi A
Eur J Dermatol; 2018 Jun; 28(3):332-337. PubMed ID: 29789272
[TBL] [Abstract][Full Text] [Related]
38. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life.
Katugampola RP; Hongbo Y; Finlay AY
Br J Dermatol; 2005 Jun; 152(6):1256-62. PubMed ID: 15948990
[TBL] [Abstract][Full Text] [Related]
39. Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities.
Blome C; Beikert FC; Rustenbach SJ; Augustin M
Arch Dermatol Res; 2013 Apr; 305(3):197-204. PubMed ID: 23266843
[TBL] [Abstract][Full Text] [Related]
40. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact.
Golbari NM; van der Walt JM; Blauvelt A; Ryan C; van de Kerkhof P; Kimball AB
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):417-421. PubMed ID: 32978847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
